Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Nanoparticle Therapy Reduces Plaque Inflammation and Lowers Risk of Heart Attack or Stroke

By BiotechDaily International staff writers
Posted on 06 Feb 2014
Image: A novel HDL nanoparticle (red) loaded with a statin drug, specifically targets and locally treats inflammatory macrophage cells (green) hiding inside high-risk plaque within blood vessels (Photo courtesy of Mount Sinai Medical Center).
Image: A novel HDL nanoparticle (red) loaded with a statin drug, specifically targets and locally treats inflammatory macrophage cells (green) hiding inside high-risk plaque within blood vessels (Photo courtesy of Mount Sinai Medical Center).
Reconstituted HDL (high-density lipoprotein) nanoparticles were used to transport inflammation-retarding statins to atherosclerotic plaques where the drug acted to reduce arterial blockage that could cause heart attack or stroke.

Inflammation is a key feature of atherosclerosis and a target for therapy. While statins are known to have potent anti-inflammatory properties, they cannot be exploited fully as an oral statin therapy due to low systemic bioavailability.

Investigators at Mount Sinai School of Medicine (New York, NY, USA) sought to concentrate the anti-inflammatory benefits of statins by incorporating them into nanoparticles that would accumulate at sites of inflammation within the blood vessels. For this purpose, they designed an injectable reconstituted high-density lipoprotein (rHDL) nanoparticle carrier vehicle capable of delivering statins directly to atherosclerotic plaques.

They reported in the January 20, 2014, online edition of the journal Nature Communications that they had initially demonstrated the anti-inflammatory effect of statin-rHDL in vitro and showed that this effect was mediated through the inhibition of the mevalonate pathway. They also applied statin-rHDL nanoparticles in vivo in an apolipoprotein E-knockout mouse model of atherosclerosis and showed that the nanoparticles accumulated in atherosclerotic lesions in which they directly affected plaque macrophages. Finally, they demonstrated that a three-month low-dose statin-rHDL treatment regimen inhibited plaque inflammation progression, while a one-week high-dose regimen markedly decreased inflammation in advanced atherosclerotic plaques.

“Not only could the HDL nanotherapy potentially avert repeat heart attacks, it may also have the power to reduce recurrent strokes caused by clots in brain arteries, ” said senior author, Dr. Willem Mulder, associate professor of radiology at Mount Sinai School of Medicine. “We envision that a safe and effective HDL nanotherapy could substantially lower cardiovascular events during the critical period of vulnerability after a heart attack or stroke. While we have much more to do to confirm clinical benefit in patients, our study shows how this nanotherapy functions biologically, and how this novel concept could potentially also work in the clinical setting to solve a critical problem. This nanotherapy would be the first of its kind.”

The optimum use for HDL-statin nanotherapy would be by injection following treatment of an arterial clot. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response. “This could potentially and very rapidly stabilize a dangerous situation,” said Dr. Mulder. “In addition, after discharge, patients would continue to use their oral statins to control LDL in their blood.”

Related Links:

Mount Sinai School of Medicine



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.